AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
48.38
+0.41 (0.85%)
Nov 10, 2026, 4:00 PM EST - Market closed
AnaptysBio Employees
AnaptysBio had 104 employees as of December 31, 2025. The number of employees decreased by 32 or 23.53% compared to the previous year. That makes AnaptysBio the 31,162nd largest employer in the world and 3,978th in the United States.
Employees
104
Change (1Y)
-32
Growth (1Y)
-23.53%
Revenue / Employee
$1,020,077
Profits / Employee
$2,519,154
Market Cap
1.45B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 104 | -32 | -23.53% | 104 | 0 |
| Dec 31, 2024 | 136 | 19 | 16.24% | 136 | 0 |
| Dec 31, 2023 | 117 | 21 | 21.88% | 117 | 0 |
| Dec 31, 2022 | 96 | -6 | -5.88% | 96 | 0 |
| Dec 31, 2021 | 102 | 8 | 8.51% | 102 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ascentage Pharma Group International | 828 |
| Ocular Therapeutix | 325 |
| Structure Therapeutics | 281 |
| Kardigan | 241 |
| Innoviva | 159 |
| Taysha Gene Therapies | 99 |
| Tyra Biosciences | 87 |
| Rapport Therapeutics | 84 |
ANAB News
- 8 hours ago - Anaptys Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 22 days ago - AnaptysBio notes Jemperli approved in U.S. for locally advanced rectal cancer - TheFly
- 22 days ago - Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer - GlobeNewsWire
- 5 weeks ago - AnaptysBio price target lowered to $60 from $70 at JPMorgan - TheFly
- 6 weeks ago - AnaptysBio price target lowered to $81 from $90 at Leerink - TheFly
- 7 weeks ago - AnaptysBio reports Q2 diluted EPS $5.11 vs. ($1.30) last year - TheFly
- 7 weeks ago - Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - AnaptysBio Earnings release: Q2 2026 - Filings